ABDX - Ticker AI Digest

Abingdon Health Plc 📰 1
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (ABDX) 1
ABDX 06:01
Abingdon Health Plc
Trading update
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health plc, a leading international developer, manufacturer, and regulatory services provider for rapid tests and med-tech, released a trading update for the financial year ended 30 June 2025 (FY25). The company reported revenue in line with market expectations of £8.6 million, up from £6.1 million in FY24, and anticipates continued strong revenue growth in FY26. Key highlights include
1. **Contract Wins and Partnerships**
Secured several large contracts, including a US$2 million deal for sexually transmitted disease tests, a £800,000 UK Research and Innovation grant for malaria diagnostics, and strategic partnerships for avian flu (H5N1) tests.
Additional CDMO contracts with European and global pharmaceutical companies, expected to generate up to US$4.5 million in revenue.
2. **Expansion and Acquisitions**
Acquired Compliance Solutions (Life Sciences) for up to £3.2 million to enhance regulatory services.
Launched Abingdon Analytical Ltd for analytical services and performance evaluation.
Opened a fully operational US CDMO service site in Madison, Wisconsin.
3. **Financial Position**
Cash at bank and in hand stood at £1.9 million as of the update.
Recent acquisitions and investments in new ventures are trading in line with expectations.
The Board targets a cash-flow positive position by 2026.
4. **Strategic Growth**
Strengthened full-service CDMO offering, integrating regulatory, R&D, scale-up, and manufacturing capabilities.
Confident outlook for FY26, supported by recent contract wins and expanded service offerings.
Dr. Chris Hand, Executive Chairman, emphasized the company’s strengthened position and confidence in future growth, driven by strategic investments and contract successes. Final FY25 results are expected in October 2025.
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 1
ABDX 06:01
Abingdon Health Plc
c. US$2.5m companion diagnostic test contract win
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health plc, a leading international developer and manufacturer of rapid <mark style="background-color:yellow">test</mark>s, announced a significant contract win valued at approximately US$2.5 million on July 31, 2025. The contract, signed with a global pharmaceutical company, involves the development, regulatory approval, and manufacturing of a companion diagnostic lateral flow point-of-care test. This full CDMO (Contract Development and Manufacturing Organization) service agreement covers feasibility, optimization, scale-up, technical transfer, and comprehensive regulatory support, with the project expected to span 24 months.
This win highlights Abingdon Healths strengthened CDMO capabilities, bolstered by recent acquisitions of IVDeology and CS Lifesciences, as well as the launch of its performance evaluation laboratory, Abingdon Analytical Ltd. The company’s integrated approach, combining diagnostic expertise, regulatory knowledge, and seamless project management, positions it as a key partner for clients seeking to bring products from concept to market.
Dr. Chris Hand, Executive Chairman, emphasized the contract’s validation of Abingdon Health’s end-to-end diagnostic solutions and its competitive advantage in companion diagnostics. The announcement underscores the company’s growth as a comprehensive med-tech contract service provider, offering services across product development, regulatory compliance, and manufacturing for global customers.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 1
ABDX 06:01
Abingdon Health Plc
Trading update
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health plc, a leading international developer, manufacturer, and regulatory services provider for rapid tests and med-tech, released a trading update for the financial year ended 30 June 2025 (FY25). The company reported revenue in line with market expectations of £8.6 million, up from £6.1 million in FY24, and anticipates continued strong revenue growth in FY26. Key highlights include
1. **Contract Wins and Partnerships**
Secured several large contracts, including a US$2 million deal for sexually transmitted disease tests, a £800,000 UK Research and Innovation grant for malaria diagnostics, and strategic partnerships for avian flu (H5N1) tests.
Additional CDMO contracts with European and global pharmaceutical companies, expected to generate up to US$4.5 million in revenue.
2. **Expansion and Acquisitions**
Acquired Compliance Solutions (Life Sciences) for up to £3.2 million to enhance regulatory services.
Launched Abingdon Analytical Ltd for analytical services and performance evaluation.
Opened a fully operational US CDMO service site in Madison, Wisconsin.
3. **Financial Position**
Cash at bank and in hand stood at £1.9 million as of the update.
Recent acquisitions and investments in new ventures are trading in line with expectations.
The Board targets a cash-flow positive position by 2026.
4. **Strategic Growth**
Strengthened full-service CDMO offering, integrating regulatory, R&D, scale-up, and manufacturing capabilities.
Confident outlook for FY26, supported by recent contract wins and expanded service offerings.
Dr. Chris Hand, Executive Chairman, emphasized the company’s strengthened position and confidence in future growth, driven by strategic investments and contract successes. Final FY25 results are expected in October 2025.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 2
ABDX 06:01
Abingdon Health Plc
Trading update
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health plc, a leading international developer, manufacturer, and regulatory services provider for rapid tests and med-tech, released a trading update for the financial year ended 30 June 2025 (FY25). The company reported revenue in line with market expectations of £8.6 million, up from £6.1 million in FY24, and anticipates continued strong revenue growth in FY26. Key highlights include
1. **Contract Wins and Partnerships**
Secured several large contracts, including a US$2 million deal for sexually transmitted disease tests, a £800,000 UK Research and Innovation grant for malaria diagnostics, and strategic partnerships for avian flu (H5N1) tests.
Additional CDMO contracts with European and global pharmaceutical companies, expected to generate up to US$4.5 million in revenue.
2. **Expansion and Acquisitions**
Acquired Compliance Solutions (Life Sciences) for up to £3.2 million to enhance regulatory services.
Launched Abingdon Analytical Ltd for analytical services and performance evaluation.
Opened a fully operational US CDMO service site in Madison, Wisconsin.
3. **Financial Position**
Cash at bank and in hand stood at £1.9 million as of the update.
Recent acquisitions and investments in new ventures are trading in line with expectations.
The Board targets a cash-flow positive position by 2026.
4. **Strategic Growth**
Strengthened full-service CDMO offering, integrating regulatory, R&D, scale-up, and manufacturing capabilities.
Confident outlook for FY26, supported by recent contract wins and expanded service offerings.
Dr. Chris Hand, Executive Chairman, emphasized the company’s strengthened position and confidence in future growth, driven by strategic investments and contract successes. Final FY25 results are expected in October 2025.
ABDX 06:01
Abingdon Health Plc
c. US$2.5m companion diagnostic test contract win
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health plc, a leading international developer and manufacturer of rapid <mark style="background-color:yellow">test</mark>s, announced a significant contract win valued at approximately US$2.5 million on July 31, 2025. The contract, signed with a global pharmaceutical company, involves the development, regulatory approval, and manufacturing of a companion diagnostic lateral flow point-of-care test. This full CDMO (Contract Development and Manufacturing Organization) service agreement covers feasibility, optimization, scale-up, technical transfer, and comprehensive regulatory support, with the project expected to span 24 months.
This win highlights Abingdon Healths strengthened CDMO capabilities, bolstered by recent acquisitions of IVDeology and CS Lifesciences, as well as the launch of its performance evaluation laboratory, Abingdon Analytical Ltd. The company’s integrated approach, combining diagnostic expertise, regulatory knowledge, and seamless project management, positions it as a key partner for clients seeking to bring products from concept to market.
Dr. Chris Hand, Executive Chairman, emphasized the contract’s validation of Abingdon Health’s end-to-end diagnostic solutions and its competitive advantage in companion diagnostics. The announcement underscores the company’s growth as a comprehensive med-tech contract service provider, offering services across product development, regulatory compliance, and manufacturing for global customers.

AI Crunch

Single-Ticker AI Crunch
ABDX signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for Abingdon Health Plc. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full ABDX AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for ABDX on 2025-08-05.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
21781004
Enterprise Value
4187469
Public Float
66.76
Broker Target
19
Shares Out
251077850
Long Interest
-
Short Interest
-
Exchange
LSE
Currency Code
GBX
ISIN
GB00BLF79J41
Market
LSE - AIM
Sector
Medical Equipment and Services
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2026-04-01
Net Debt
-890000.0
Cash
1918000.0
EPS
-0.01
Net Income
-3415000.0
Revenue
8429000.0
Enterprise Value
4187469
Trailing PE
-
Forward PE
53.1915
Price Sales TTM
2.2755
Price Book MRQ
3.1878
EV Revenue
1.8102
EV EBITDA
-0.2499

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
44.9753
Institutions As Of
2025-11-04
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
0
Sale Director Dealing
0
Purchase TR1
6
Sale TR1
1
Broker Coverage Rows
0
Institution Holders Tracked
5
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

1 live catalyst just hit ABDX.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2025-08-05 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
1 Today
Catalyst Pulse
Abingdon Health Plc has fresh news flow feeding the chart narrative.
AI Charts Studio
ABDX Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2025-08-05 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast 2.17%
RSI Gauge
Price Change
AI Forecast